Investigational New Drugs Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Xanthohumol microbiome and signature in healthy adults (the XMaS trial): a phase I triple-masked, placebo-controlled clinical trial
DiscussionThis phase I clinical trial of xanthohumol will assess safety and tolerability in healthy adults, collect extensive biomarker data for assessment of potential mechanism(s), and provide comparison data necessary for future phase II trials in chronic disease(s). The design and robustness of the planned safety and mechanistic evaluations planned provide a model for drug discovery pursuits from natural products.Trial registrationClinicalTrials.govNCT03735420. Registered on November 8, 2018 (Source: Trials)
Source: Trials - October 6, 2020 Category: Research Source Type: clinical trials

FDA Grants Inhaled Use IND for RLF-100 (aviptadil) to Treat Patients with Moderate and Severe COVID-19 Aiming to Prevent Progression to Respiratory Failure
Radnor, PA and Geneva, CH, August 6, 2020– NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF)“Relief” today announced that NeuroRx has been granted Investigational New Drug (IND) permission to test RLF-100... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 6, 2020 Category: Pharmaceuticals Source Type: clinical trials

Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma
Condition: Multiple Myeloma Intervention: Drug: JNJ-68284528 Sponsor: Janssen Research & Development, LLC No longer available (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 1, 2020 Category: Research Source Type: clinical trials

Anivive Repurposes Veterinary Drug GC376 for COVID-19 And Submits Pre-IND to FDA
LONG BEACH, Calif. -- May 26, 2020 -- Anivive Lifesciences, a biotechnology company focused on developing first-in-class therapeutics for veterinary patients, has filed a pre-Investigational New Drug (pIND) request with the Food and Drug... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 26, 2020 Category: Pharmaceuticals Source Type: clinical trials

INOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine
PLYMOUTH MEETING, Pa., April 6, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the U.S. Food and Drug Administration has accepted the company ' s Investigational New Drug (IND) application for INO-4800, its... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 6, 2020 Category: Pharmaceuticals Source Type: clinical trials

NuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer
EDINBURGH, United Kingdom, Oct. 25, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for its Phase III study (NuTide:121) of the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 25, 2019 Category: Pharmaceuticals Source Type: clinical trials

Seelos Therapeutics Announces Investigational New Drug Application Submission for SLS-005
NEW YORK, July 17, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - July 17, 2019 Category: Pharmaceuticals Source Type: clinical trials